BioVie’s Bezisterim improves Parkinson’s symptoms in patients with elevated inflammation in Phase 2 trial

• BioVie presented Phase 2 SUNRISE-PD results for bezisterim in early Parkinson’s disease at the American Neurological Association meeting, October 17-20, 2026.
• The 57-patient, placebo-controlled trial tested treatment for 12 weeks, with overall efficacy outcomes generally favoring bezisterim.
• Patients with higher baseline inflammation showed statistically significant improvements in motor and non-motor symptoms compared with placebo.
• Bezisterim was well tolerated, with fewer treatment-emergent adverse events than placebo; neither group reported severe or serious adverse events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200800PRIMZONEFULLFEED9848721) on October 20, 2026, and is solely responsible for the information contained therein.